Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2011-03-15
2011-03-15
Tsang, Cecilia (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S252050, C514S260100, C514S312000, C514S359000, C514S381000, C514S414000, C540S450000, C544S238000, C544S278000, C544S354000
Reexamination Certificate
active
07906513
ABSTRACT:
The present invention relates to novel hydrazide-containing compounds of Formula I or Formula II, including pharmaceutically acceptable salts, esters, or prodrugs thereof which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
REFERENCES:
patent: 6608027 (2003-08-01), Tsantrizos et al.
patent: 7253160 (2007-08-01), Njoroge et al.
patent: 2005/0164921 (2005-07-01), Njoroge et al.
patent: 2007/0099825 (2007-05-01), Stanley et al.
patent: 2008/0267916 (2008-10-01), Gai et al.
patent: 2008/0267917 (2008-10-01), Niu et al.
patent: WO2005/051980 (2005-06-01), None
Ronn et al. Evaluation of a diverse set of potential P1 carboxylic acid bioisosteres in hepatitis C virus NS3 protease inhibitors. Biorganic and Medicinal Chemistry. Jun. 15, 2007, available online Apr. 4, 2007, vol. 15, No. 12, pp. 4057-4068.
U.S. Appl. No. 11/740,440, filed Apr. 26, 2007, Yonghua Gai, et al.
U.S. Appl. No. 11/740,502, filed Apr. 26, 2007, Deqiang Niu, et al.
Elliott Eric L.
Moore Joel D.
Or Yat Sun
Wang Zhe
Cordero Garcia Marcela M
Edwards Angell Palmer & & Dodge LLP
Enanta Pharmaceuticals, Inc.
Hsi Jeffrey D.
Kim Dwight D.
LandOfFree
Hydrazide-containing hepatitis C serine protease inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Hydrazide-containing hepatitis C serine protease inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Hydrazide-containing hepatitis C serine protease inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2736760